This website was developed by Paratek Medical Affairs professionals as a resource for healthcare professionals practicing in the United States.
The information provided on this website is for informational purposes and is not intended to promote the use of any product.
CHEST 2025
October 19-22 2025
Chicago, IL
ID Week 2025
October 19-22, 2025
Atlanta, GA
The below CME program was supported by Paratek Pharmaceuticals, Inc
CABP
Practical Considerations for the Management of Bacterial Community-Acquired Pneumonia
Objectives:
1. Discuss the diagnostic criteria and classification of CAP
2. Apply evidence-based approaches to treatment selection for severe bacterial CAP
3. Review the guidelines for therapeutic management of CAP
4. Explain how to integrate clinical evidence into treatment selection for patients with comorbidities.
Available until May 2, 2026
--------------------------------------------------------------------------------------------------------------------------------------------------------------------
The CME program was supported by an independent educational grant from Paratek Pharmaceuticals, Inc. The materials presented in the CME program was not created or influenced by Paratek and do not reflect the views of Paratek. These materials may discuss uses and dosages for therapeutic products that may not be approved by the FDA and are not intended to promote any product or indication outside of an FDA-approved use. Prescribers should consult the FDA-approved Prescribing Information for each individual product.
Please check back for updates
By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.
